Assyro AI

Purple Book product · Interchangeable

Hulio

adalimumab-fkjp

351(k) InterchangeableBLA 761154RxLicensed Biocon Biologics Inc.

Jul 06, 2020

Approved

Interchangeable

License type

Rx

Marketing

66

Listed patents

Hulio (adalimumab-fkjp) is a Interchangeable referencing adalimumab, licensed under a 351(k) BLA in 2020 and marketed by Biocon Biologics Inc.. As an interchangeable biosimilar it may be substituted for the reference product at the pharmacy without prescriber involvement, subject to state law. The Purple Book lists 66 published patents for this product.

Sourced from the FDA Purple Book · verified Jul 02, 2026

Key dates

  1. Approval

    Approval date of this BLA submission.

    Jul 06, 2020

    6 yr 1 mo ago

  2. Today

Pharmaceutical detail

Strength

20MG/0.4ML

Dosage form

Injection

Route

Subcutaneous

Presentation

Pre-Filled Syringe

Center

CDER

License number

2324

Product number

003

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Reference product family

View full family

Biosimilar of adalimumab (Humira)

Patent list (66)

Patents published in the FDA Purple Book Patent List for this product, with expiration date and source link.
PatentExpiresInSource
8,911,737Jun 05, 20224 yr 2 mo agoFDA
8,974,790Jun 05, 20224 yr 2 mo agoFDA
8,992,926Jun 05, 20224 yr 2 mo agoFDA
9,546,212Jun 05, 20224 yr 2 mo agoFDA
6,805,686May 06, 20233 yr 3 mo agoFDA
8,906,373Jul 18, 20233 yr 1 mo agoFDA
9,067,992Jul 18, 20233 yr 1 mo agoFDA
9,085,620Jul 18, 20233 yr 1 mo agoFDA
9,090,689Jul 18, 20233 yr 1 mo agoFDA
8,961,973Apr 11, 20251 yr 3 mo agoFDA
8,961,974Apr 11, 20251 yr 3 mo agoFDA
8,986,693Apr 11, 20251 yr 3 mo agoFDA
9,061,005Apr 11, 20251 yr 3 mo agoFDA
9,187,559Apr 11, 20251 yr 3 mo agoFDA
9,512,216Apr 11, 20251 yr 3 mo agoFDA
8,808,700May 16, 20262 mo agoFDA
11,083,792Apr 04, 2027in 9 moFDA
8,231,876Apr 04, 2027in 9 moFDA
8,883,156Apr 04, 2027in 9 moFDA
8,895,009Apr 04, 2027in 9 moFDA
8,906,372Apr 04, 2027in 9 moFDA
8,916,153Apr 04, 2027in 9 moFDA
9,096,666Apr 04, 2027in 9 moFDA
9,102,723Apr 04, 2027in 9 moFDA
9,273,132Apr 04, 2027in 9 moFDA
9,328,165Apr 04, 2027in 9 moFDA
9,913,902Apr 04, 2027in 9 moFDA
8,926,975Jun 08, 2027in 11 moFDA
8,715,664Jul 24, 2027in 1 yrFDA
8,663,945Sep 13, 2027in 1 yr 2 moFDA
8,906,646Sep 13, 2027in 1 yr 2 moFDA
8,911,964Sep 13, 2027in 1 yr 2 moFDA
9,090,867Sep 13, 2027in 1 yr 2 moFDA
9,234,032Sep 13, 2027in 1 yr 2 moFDA
9,284,371Sep 13, 2027in 1 yr 2 moFDA
8,889,136Oct 09, 2027in 1 yr 3 moFDA
9,284,370Jun 10, 2028in 1 yr 11 moFDA
9,669,093Jun 10, 2028in 1 yr 11 moFDA
11,167,030Nov 28, 2028in 2 yr 5 moFDA
11,191,834Nov 28, 2028in 2 yr 5 moFDA
9,085,619Nov 28, 2028in 2 yr 5 moFDA
8,420,081Jan 13, 2030in 3 yr 7 moFDA
8,999,337Feb 06, 2031in 4 yr 7 moFDA
9,624,295Mar 31, 2031in 4 yr 9 moFDA
8,708,968Jan 24, 2032in 5 yr 7 moFDA
9,339,610Jan 24, 2032in 5 yr 7 moFDA
9,062,106Apr 26, 2032in 5 yr 10 moFDA
9,090,688Apr 26, 2032in 5 yr 10 moFDA
9,505,834Apr 26, 2032in 5 yr 10 moFDA
9,522,953Apr 26, 2032in 5 yr 10 moFDA
9,683,033Apr 26, 2032in 5 yr 10 moFDA
9,957,318Apr 26, 2032in 5 yr 10 moFDA
9,085,618Mar 14, 2033in 6 yr 9 moFDA
9,181,337Mar 14, 2033in 6 yr 9 moFDA
9,181,572Mar 14, 2033in 6 yr 9 moFDA
9,290,568Mar 14, 2033in 6 yr 9 moFDA
9,334,319Mar 14, 2033in 6 yr 9 moFDA
9,346,879Mar 14, 2033in 6 yr 9 moFDA
9,359,434Mar 14, 2033in 6 yr 9 moFDA
9,499,616Mar 14, 2033in 6 yr 9 moFDA
9,708,400Mar 14, 2033in 6 yr 9 moFDA
9,315,574Apr 21, 2033in 6 yr 10 moFDA
9,150,645May 13, 2033in 6 yr 11 moFDA
9,266,949May 13, 2033in 6 yr 11 moFDA
9,499,614Mar 14, 2034in 7 yr 9 moFDA
9,550,826Nov 14, 2034in 8 yr 5 moFDA

Source provenance

Source kind · Advanced Search
Checked Jul 02, 2026
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

Change history

  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Frequently asked questions

When do Hulio's patents expire?

The FDA Purple Book lists 66 published patents for Hulio, with the last listed patent expiring Nov 14, 2034. Every patent below links to its FDA source record so you can verify the expiration date.

Is Hulio a biosimilar?

Yes. Hulio is a Interchangeable referencing adalimumab, licensed under a 351(k) BLA.

Is Hulio interchangeable?

Yes. Hulio carries an FDA interchangeability designation, so it may be substituted for the reference product at the pharmacy without prescriber involvement, subject to state law.

What is Hulio's BLA number?

Hulio is licensed under BLA 761154, held by Biocon Biologics Inc..

When was Hulio approved by the FDA?

Hulio was approved by the FDA on Jul 06, 2020.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.